CA-LAMBDATEST
14.5.2024 19:01:37 CEST | Business Wire | Press release
LambdaTest, a leading cloud-based unified testing platform, is excited to announce its integration with BugHerd, the Australian-based website feedback and bug tracking tool. This collaboration is designed to enhance the efficiency of identifying and logging website bug reports during the testing phase.
BugHerd is a popular website bug-tracking tool that aids organizations by enabling them to easily create and collect bug reports, and track feedback. This streamlines communication by allowing clear pinpointing of issues, while also offering task management features to track bug progress and resolution within development teams.
This integration empowers users to effortlessly report bugs discovered during LambdaTest's comprehensive cross-browser testing sessions directly to their BugHerd project. With a single click, users can generate a new BugHerd task complete with essential details, including screenshots, browser, and operating system information, and the ability to assign the task to a specific team member. This eliminates the need for manual data entry and ensures all critical information is captured for efficient bug resolution.
Mayank Bhola, Co-Founder and Head of Product at LambdaTest, commented on the integration saying, "We're thrilled to offer this integration with BugHerd. It aligns perfectly with our mission to make the lives of testers and developers easier. By combining our efforts, we're simplifying the bug tracking process which is often a major bottleneck in web development."
Setting up the BugHerd integration is straightforward—users just need to enter their BugHerd API token in the LambdaTest settings. This simple step will connect their testing workflow directly to BugHerd, enabling them to start logging bugs immediately.
This new feature is designed to be seamless and easy to use, ensuring that even teams without technical expertise can efficiently enhance their web projects. Users can effortlessly manage their testing directly from LambdaTest and see their issues updated in BugHerd without any complications.
"This integration with LambdaTest underscores our commitment to agencies and web developers by allowing them to seamlessly link browser testing with direct feedback, thereby shortening project timelines and enhancing client satisfaction," said Stephen Neville, CEO of BugHerd.
This partnership between BugHerd and LambdaTest represents a significant step forward in making web testing more integrated and efficient, allowing development teams to deliver higher-quality websites faster and with fewer issues.
For more information about BugHerd’s integration with LambdaTest, please visit https://www.lambdatest.com/support/docs/bugherd-integration/
About LambdaTest
LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO), ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
- Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.
- HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster.
For more information, please visit: https://lambdatest.com
About BugHerd
BugHerd is an Australian-based software company whose website feedback platform is used all around the world by creative and web development agencies, SaaS companies, education, and online learning organizations.
The company officially launched to the SaaS market in 2011 and was one of the first-ever Australian teams to grace the US-based startup program 500 Startups and the Australian-based Startmate.
BugHerd gained popularity by carving a niche in the Web Developer and Designer software tool market. It solved the difficulty they faced getting contextual website feedback from non-technical folk.
With Stephen Neville at the helm as CEO, the BugHerd team is committed to helping agencies run their website development projects to budget and on time, keeping their clients happy so that they come back for more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514577994/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Strengthens Its Leadership Team With the Appointment of Marion Ghibaudo as Chief Technology Officer16.9.2026 08:00:00 CEST | Press release
An expert in scaling medical innovations, Marion Ghibaudo joins Okomera as the company advances toward industrial deployment. Okomera, a TechBio company pioneering next-generation cancer care through the development of a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the appointment of Marion Ghibaudo as Chief Technology Officer. She will spearhead the company’s technology and innovation strategy and lead the industrial deployment of its integrated hardware, software, and biological platform. Marion Ghibaudo will join Okomera’s Executive Committee and report to CEO Silvère Lucquin. In parallel, Raphaël Tomasi, Okomera’s co-founder and former CTO, transitions to the role of VP Platform, ensuring continuity in the development of the company’s technology platform. Marion’s appointment comes at a key stage in Okomera’s growth as the company advances toward pilot studies, industrial scale-up, and commercialization. Okomer
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing16.9.2026 07:00:00 CEST | Press release
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121 Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1 These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3 Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom